Evaluation of Agile Designs in First-in-Human (FIH) Trials—A Simulation Study
Journal Title: The AAPS Journal - Year 2009, Vol 11, Issue 4
Abstract
The online version of this article (doi:10.1208/s12248-009-9141-0) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Itay Perlstein, James A. Bolognese, Rajesh Krishna, John A. Wagner
Safety of β2-Agonists in Asthma: Linking Mechanisms, Meta-Analyses and Regulatory Practice
An epidemic of asthma fatalities in the 1970s prompted a series of case-control studies which indicated that short acting β-agonists increased the risk of death. Subsequent mechanistic and pharmacodynamic studies...
The prediction of plasma and brain levels of 2,3,5,6-tetramethylpyrazine following transdermal application
The purpose of this study was to construct a pharmacokinetic (PK) model and to determine PK parameters of 2,3,5,6-tetramethylpyrazine (TMP) after application of TMP transdermal delivery system. Data were obtained in Spra...
Modeling NSCLC Progression: Recent Advances and Opportunities Available
Non-small cell lung cancer (NSCLC) is one of the leading causes of death around the world with an estimated 5-year relative survival rate of 16% at diagnosis. Development of drugs treating NSCLC is not easy, and the succ...
Predictions of In Vivo Prolactin Levels from In Vitro Ki Values of D2 Receptor Antagonists Using an Agonist–Antagonist Interaction Model
Prolactin elevation is a side effect of all currently available D2 receptor antagonists used in the treatment of schizophrenia. Prolactin elevation is the result of a direct antagonistic D2 effect blocking the tonic inhi...
Assessing the cost-effectiveness of pharmacogenomics
The use of pharmacogenomics to individualize drug therapy offers the potential to improve drug effectiveness, reduce adverse side effects, and provide cost-effective pharmaceutical care. However, the combinations of dise...